Baseline characteristics and safety of a cohort of patients with chronic lymphocytic lymphoma and small lymphocytic lymphoma treated with idelalisib in combination with rituximab: An early access program
Latest Information Update: 10 Sep 2016
At a glance
- Drugs Idelalisib (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 10 Sep 2016 New trial record